MEETING OVERVIEW | We are pleased to invite you to "Practical Strategies for the Management of CML," a five-city meeting series featuring Elias Jabbour, MD, of The University of Texas M. D. Anderson Cancer Center in Houston, Texas. Dr Jabbour will be joined by a local expert in each city to discuss clinical scenarios highlighting important practice changing data that can be readily applied to the daily management of chronic myeloid leukemia (CML). |
DATES/LOCATIONS |
Thursday, June 16
Restaurant RDG
1800 Post Oak Boulevard
Houston, TX 77056
Thursday, June 23
The Palm
9001 Santa Monica Boulevard
West Hollywood, CA 90069
Tuesday, July 12
The Prime Rib
1701 Locust Street
Philadelphia, PA 19103 |
Wednesday, June 22
Morton's The Steakhouse
1050 Connecticut Avenue NW
Washington, DC 20036
Tuesday, June 28
The Chicago Firehouse Restaurant
1401 S. Michigan Avenue
Chicago, IL 60605
|
|
AGENDA |
| 6.30 PM |
Dinner service begins
|
| 6.45 PM |
Welcome and introduction
|
| 6.50 PM |
Clincial Case #1
Newly diagnosed CML: Optimizing approaches in first-line therapy
|
| 7.15 PM |
Clinical Case #2
Second-line therapy for chronic phase CML: Determinants for selecting the best option
|
| 7.40 PM |
Overcoming treatment barriers in the management of CML: An open dialogue
|
| 8.00 PM |
Adjourn |
|
COURSE DIRECTOR |
Elias Jabbour, MD
The University of Texas M. D. Anderson Cancer Center
Houston, Texas
|
FACULTY
|
|
Ronald Paquette, MD
Jonsson Comprehensive Cancer Center at UCLA
Los Angeles, California
|
David L. Porter, MD
University of Pennsylvania Medical Center
Philadelphia, Pennsylvania
|
Adan Rios, MD
The University of Texas Medical School
Houston, Texas
|
Jamile Shammo, MD, FASCP, FACP
Rush University Medical Center
Chicago, Illinois
|
Imad A. Tabbara, MD, FACP
The George Washington University Hospital
Washington, DC
|
|
|
TARGET AUDIENCE | Practical Strategies for the Management of CML is designed for hematologists, oncologists, and other physicians involved and/or interested in the management of patients with chronic myeloid leukemia. |
EDUCATIONAL OBJECTIVES |
Upon completion of this educational activity, participants should be able to:
• Discuss recent clinical trial data evaluating the use of tyrosine kinase inhibitors in the management of patients with newly diagnosed CML so that the optimal therapy can be selected and implemented on an individual patient basis.
• Evaluate clinical and molecular features in determining second-line therapy in order to appropriately manage patients with chronic phase CML who have experienced a resistance or intolerance to first-line tyrosine kinase inhibitor therapy.
• Identify strategies for overcoming barriers to treatment that are unique to the community oncology setting. |
 DISCLOSURE OF CONFLICTS OF INTEREST | prIME Oncology assess conflicts of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity. |
DISCLOSURE OF UNLABELED USE OF AGENTS | This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food & Drug Administration or the European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings. |
DISCLAIMER | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. |
|
|
|
FEE INFORMATION | There is no fee for this activity, but registration is required. Space is limited to the first 20 practicing physicians who register. |
SPONSORSHIP |
This activity is sponsored by prIME Oncology.
|
SUPPORT |
Support for this activity has been provided by an unrestricted educational grant from Novartis Oncology.
|
CONTINUING EDUCATION STATEMENT | prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.
prIME Oncology designates this live educational activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
|
